Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial

  1. Mateos, M.-V.
  2. Oriol, A.
  3. Martínez-López, J.
  4. Gutiérrez, N.
  5. Teruel, A.-I.
  6. de Paz, R.
  7. García-Laraña, J.
  8. Bengoechea, E.
  9. Martín, A.
  10. Mediavilla, J.D.
  11. Palomera, L.
  12. de Arriba, F.
  13. González, Y.
  14. Hernández, J.-M.
  15. Sureda, A.
  16. Bello, J.-L.
  17. Bargay, J.
  18. Peñalver, F.-J.
  19. Ribera, J.-M.
  20. Martín-Mateos, M.-L.
  21. García-Sanz, R.
  22. Cibeira, M.-T.
  23. Ramos, M.-L.M.
  24. Vidriales, M.-B.
  25. Paiva, B.
  26. Montalbán, M.-A.
  27. Lahuerta, J.-J.
  28. Bladé, J.
  29. Miguel, J.-F.S.
  30. Show all authors +
Journal:
The Lancet Oncology

ISSN: 1470-2045

Year of publication: 2010

Volume: 11

Issue: 10

Pages: 934-941

Type: Article

DOI: 10.1016/S1470-2045(10)70187-X GOOGLE SCHOLAR

Sustainable development goals